68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

68Ga-grazytracer is designed to target granzyme B, and showed excellent in vivo metabolic stability and favorable targeting efficiency during immune responses. 68Ga-grazytracer PET/CT could directly display the killing effect of CD8+T cells on tumor. All enrolled patients underwent the same 68Ga-grazytracer PET/CT imaging.